{"product_id":"scramble-shrna-aav-serotype-2-aav-aav2-gfp-u6-shrna-bhv21600468","title":"Scramble shRNA (AAV serotype 2) AAV (AAV2-GFP-U6-shRNA)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eScramble shRNA (AAV serotype 2) AAV (AAV2-GFP-U6-shRNA) is an AAV vector packaged in AAV2 under the U6 promoter that delivers \u003cstrong\u003escrambled shRNA\u003c\/strong\u003e to mammalian cells. Researchers commonly use this vector for negative control for shrna\/mirna knockdown experiments.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapsid (serotype):\u003c\/strong\u003e AAV2. efficient neuronal transduction with limited spread; widely used for in vitro work and for focal CNS injections.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter:\u003c\/strong\u003e U6 — RNA polymerase III promoter used for short non-coding RNA (shRNA\/sgRNA\/miRNA) expression.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayload:\u003c\/strong\u003e scrambled shRNA — non-targeting short hairpin RNA used as a negative control for shRNA knockdown experiments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenome backbone:\u003c\/strong\u003e Recombinant AAV (single-stranded unless explicitly noted as scAAV) flanked by AAV2 ITRs.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eScrambled (non-targeting) shRNA and miRNA sequences are designed to fold into the same secondary structure as a targeting shRNA\/miRNA but to lack significant complementarity to any mammalian transcript. They control for non-sequence-specific effects of RNAi machinery engagement, AAV transduction, capsid uptake, and innate immune sensing of double-stranded RNA intermediates.\u003c\/p\u003e\u003cp\u003eKnockdown should always be reported relative to a matched scrambled control delivered with the same vector backbone, capsid, and titer.\u003c\/p\u003e\u003cp\u003eThe U6 promoter — RNA polymerase III promoter used for short non-coding RNA (shRNA\/sgRNA\/miRNA) expression — drives expression of the payload from the AAV cassette in this product. Promoter–capsid combinations together determine where and at what level the payload is expressed.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eRobust controls for AAV-shRNA studies remain a focus area, especially given concerns about saturation of endogenous miRNA machinery at high shRNA doses.\u003c\/li\u003e\n\u003cli\u003eAAV vector engineering — including capsid evolution, capsid shuffling, and rational design — continues to expand the spectrum of accessible tissues and cell types.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\u003cli\u003eNegative control for AAV-shRNA or AAV-miRNA knockdown studies.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eUse this product within experimental designs that include matched controls (capsid, promoter, dose, route) and a transduction validation step before interpreting payload-specific phenotypes.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConfirm transduction efficiency in the target cell population before drawing payload-specific conclusions; reporter signal alone validates only that the vector reached and expressed in the cells.\u003c\/li\u003e\n\u003cli\u003eMatch AAV dose, capsid, promoter, and route across all conditions when comparing payload to control; differences in any of these confound payload-specific interpretation.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles of AAV stocks — aliquot upon first thaw.\u003c\/li\u003e\n\u003cli\u003eAAV biology, including tropism, can differ between species, strains, ages, and routes — confirm in your specific system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- Sources (internal):\n- Olejniczak M, Galka P, Krzyzosiak WJ. Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res. 2010. https:\/\/academic.oup.com\/nar\/article\/38\/1\/1\/1019345\n- Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther. 2008. https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(16)33063-5\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"AAV2 \/ 1x10^13 GC\/ml \/ 20 µL","offer_id":53286505087341,"sku":"7041","price":495.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/scramble-shrna-aav-serotype-2-aav-aav2-gfp-u6-shrna-bhv21600468","provider":"BioHippo","version":"1.0","type":"link"}